|
|
||||||||
Brief Communications |
lknur Ak, MD1
, MD3
1 Department of Nuclear Medicine, Osmangazi University, Eski
ehir, Turkey
2 Department of Medical Genetics, Osmangazi University, Eski
ehir, Turkey
3 Department of Hematology, Osmangazi University, Eski
ehir, Turkey
4 Department of Radiology, Division of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands
ABSTRACT
99mTc-d,1-hexamethylpropyleneamine oxime (HMPAO) is widely used as a labeling agent for leukocytes in the diagnosis of inflammatory or infectious foci. Cytotoxicity studies have indicated that intracellular labeling of leukocytes with 111In compounds may have severe detrimental effects on the cells. Methods: In this study, the radiotoxic effects on mixed lymphocytes after labeling with 99mTc-HMPAO was investigated using the cytokinesis-blocked micronucleus assay and chromosomal aberration assay. Results: Whereas negligible numbers of chromosome abnormalities were noted in unlabeled lymphocytes, the labeled lymphocytes showed multiple aberrations of various types, including dicentric, tricentric, and fivecentric chromosomes; centric rings; chromosome and chromatid type breaks; and acentric fragments. Conclusion: Heavily aberrant lymphocytes are seen in 99mTc-HMPAOlabeled mixed leukocytes after routine clinical procedures. It is unlikely, however, that this would cause detrimental effects, such as lymphoid malignancy, as these cells would normally be eliminated through apoptosis or phagocytosis.
Key Words: 99mTc-HMPAO leukocyte labeling radiation damage chromosomal aberrations lymphocytes
This article has been cited by other articles:
![]() |
C. d. L. Vaylet, N. Colas-Linhart, A. Petiet, B. Bok, I. Ak, E. K.J. Pauwels, and A. D. Tates White Blood Cell Labeling with 99mTc-HMPAO J. Nucl. Med., April 1, 2003; 44(4): 657 - 658. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |